[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postmenopausal-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postmenopausal-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,75,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100603030","smart-technology-based-intervention-and-monitoring-of-physical-and-mental-health-in-early-postmenopausal-women-100603030",false,"NCT07131215","Smart Technology-Based Intervention and Monitoring of Physical and Mental Health in Early Postmenopausal Women","Inclusion Criteria:\n\n* 45 to 65-year-old postmenopausal women\n* At least 12 months of amenorrhea\n* Within 6 years after menopause\n\nExclusion Criteria:\n\n* Exercised more than twice a week for at least 30 minutes per session\n* Received hormone therapy in the past three months\n* Neurological disease (e.g., spinal cord injury, multiple sclerosis, stroke) or cardiovascular diseases\n* History of pelvic or prolapse surgery (excluding cesarean section)\n* History of malignancy affecting the bladder, urethra, uterus, ovary, cervix, or rectum\n* Using medications that could affect heart rate or mood\n* Body mass index (BMI) \\> 35 kg\u002Fm²","FEMALE","40 Years","65 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to compare the short-term and long-term effects of an 8-week home-based multimodal exercise program, delivered through a smartphone app, on quality of life, muscle function, and physical performance in early postmenopausal women.",[26,27,28],"Postmenopausal","Postmenopausal Disorder","Menopause","RECRUITING","2026-04-09",{"date":32,"type":33},"2026-04-14","ACTUAL",{"date":35,"type":33},"2025-08-15",{"date":37,"type":20},"2028-07-31",{"name":39,"class":40},"YI-JU TSAI","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":15,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":41},"100424514","phase-4-prevention-of-recurrent-uti-using-vaginal-testosterone-versus-placebo-placebo-100424514","NCT04807894","Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo","Prevention of Recurrent Urinary Tract Infection Using Vaginal Testosterone Versus Placebo","PIVoT","Inclusion Criteria:\n\n* 60-90 yo Female\n* Postmenopausal\n* Recurrent UTIs (three or more culture confirmed symptomatic episodes of UTI or two or more in the past 6 months).\n* English Proficiency\n* Unable or unwilling to use topical estrogen.\n* Patients with history of or current endometrial or breast cancer and current aromatase inhibitor therapy may also be included in study.\n* Patient on oral estrogen therapy may be included.\n* Patient with slings, prior vaginal surgery or pessary may be included.\n\nExclusion Criteria:\n\n* Current UTI\u002F Dipstick and culture positive (\\> trace leukocytes or nitrites)\n* Antibiotic (vaginal or oral) use in the last 4 weeks\n* Current sexually transmitted infection\n* Chronic Foley catheter use or chronic ureteral stent placement.\n* Vaginal probiotic use in the last 4 weeks\n* Patient currently using vaginal estrogen.\n* Post-void Residual Volume \\>150 mL or current diagnosis of urinary retention\n* Non-evaluated hematuria (\\> trace on dipstick, microscopic, gross)\n* Unable to complete study tasks or comply with follow up.",true,"60 Years","90 Years",{"count":54,"type":20},100,[56],"PHASE4","Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract infections (UTI). This is believed to be due to hormonally induced changes in the vaginal flora associated with menopause. After menopause, there is a chemical changes in the vagina that may predispose to bacterial infections.\n\nThe role of vaginal estrogen creams to restore vaginal atrophy and prevent urinary tract infections has been well characterized. Vaginal testosterone (VT) application use in postmenopausal breast cancer patients on aromatase inhibitors have been shown to improve vaginal pH, vaginal atrophy symptom scores, dyspareunia, and vaginal dryness. Although testosterone has been used to improve sexual function in postmenopausal women, the effects of VT on vaginal flora and recurrent UTIs are unknown.\n\nThe purpose of this study is to determine whether topically applied vaginal testosterone cream is more effective than placebo in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections and to ascertain the effects of topical estrogen on the vaginal pH and flora.",[59,60,27],"Recurrent Urinary Tract Infection","Vaginal Atrophy",[62,63,64,65],"urinary tract infections,","postmenopausal women","vaginal atrophy,","vaginal flora","2025-11-04",{"date":68,"type":33},"2025-11-05",{"date":70,"type":33},"2020-11-01",{"date":72,"type":20},"2026-12-31",{"name":74,"class":40},"Maimonides Medical Center",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":50,"sex":15,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":41},"100556849","phase-2-the-muse-study-for-menopausal-arthralgia-100556849","NCT06530459","The MUSE Study for Menopausal Arthralgia","The MUScle Strengthening Exercises and Estrogen (MUSE) Randomized Controlled Trial for Menopausal Arthralgia","MUSE","INCLUSION CRITERIA:\n\n1. Patients with muscle stiffness and joint discomfort in various sites, including hands, knees, back, hips, and\u002For shoulders. Patients with pain in only one isolated joint would not be accepted.\n2. Arthralgia symptoms with onset, or has become worse, over the perimenopausal or early postmenopausal period (within 5 years of the menopause).\n3. Women should be at the menopause transition, less than or equal to 59 years old at the time of enrollment, or within 5 years of menopause whichever is earlier.\n\n   .\n4. Arthralgia for at least 3 months (pain lasting beyond normal injury healing period)\n5. Community-dwelling and able to ambulate independently.\n\nEXCLUSION CRITERIA:\n\n1. History of thrombo-embolic diseases, strokes, ischemic heart disease, dementia or psychiatric disorders, active liver disease or renal impairment, severe hyperlipidemia, gout, thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, or other chronic inflammatory conditions.\n2. Pregnancy\n3. Non-adherence to national guidelines for breast cancer screening\n4. High risk for breast cancer\n5. Any joint surgery within the last 6 months\n6. Severe obesity: BMI\\>35\n7. Migraine with aura\n8. Poorly controlled diabetes\n9. Use of any form of female hormone supplementation within the past 12 weeks.\n10. High venous thromboembolism risk\n11. Current cholecystitis, fibroids, or undiagnosed abnormal uterine bleeding.\n12. Current smoker.\n13. History of endometrial, ovarian, peritoneal, cervical, breast or endocrine-dependent cancers.\n14. Receiving treatment for any form of cancer.\n15. History of fragility bone fractures within the 2 years.\n16. Any other cognitive, musculoskeletal, neurological, and cardiorespiratory condition affecting one's ability to participate in the study.","30 Years","59 Years",{"count":54,"type":20},[87,88],"PHASE2","PHASE3","The investigators plan to conduct a pilot 4-arm, randomized study comprising the following interventions: muscle strengthening exercises (MSE) alone, estrogen therapy (ET) alone, and a combination of MSE and ET, compared to usual care in women with menopausal arthralgia. The aim of this pilot study is to assess the feasibility, patient acceptability, and patient perspectives and logistics of delivering interventions, and practicability of outcome assessment tools in this 4-arm study over a 12-week period.",[91,28,92,93,27],"Arthralgia","Perimenopausal Disorder","Joint Pain",[95,96,97,98,99],"Menopausal hormone therapy","Muscle strength","Exercise","Randomized controlled trial","Midlife women","2024-07-26",{"date":102,"type":33},"2024-07-31",{"date":104,"type":20},"2024-08-01",{"date":106,"type":20},"2028-04",{"name":108,"class":40},"National University Hospital, Singapore",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":50,"sex":15,"minAge":117,"maxAge":17,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":41},"100337385","inspiratory-muscle-training-x-cardiobreath-app-effects-on-vagal-modulation-and-pulse-wave-velocity-100337385","NCT03672760","Inspiratory Muscle Training X CardioBreath App Effects On Vagal Modulation And Pulse Wave Velocity","Inspiratory Muscle Training X CardioBreath App Effects On Vagal Modulation And Pulse Wave Velocity On Normotensive Postmenopause Women : Randomized Clinical Trial","CardioBreath","Inclusion Criteria:\n\n* Follicle Stimulating Hormone (FSH)\\>35mui\u002Fml\n* minimum 12 months amenorrhea\n* sedentary life style (less than 150 minutes per week of exercise)\n\nExclusion Criteria:\n\n* Hypertension\n* Diabetes\n* Obesity\n* Use of Betablockers\n* recent cardiovascular events or surgery\n* renal alterations\n* respiratory and\u002For motor pathologies\n* smoking\n* BMI\\>29,9","45 Years",{"count":119,"type":20},24,[23],"Existing data points to relevant beneficial effects of respiratory exercises on cardiovascular health, with special regards to decreases on arterial pressure and improves on autonomic and vascular profiles, though mechanistics of such results have not yet been cleared. Among the available ways to perform respiratory exercises, there is the highly recommended Inspiratory Muscle Training (IMT) and slow breathing exercises like Yoga pranayamas. Lately, the development of new technologies has allowed the use of Apps to perform respiratory exercises. This study will be take the just developed CardioBreath®App to validate it as a tool to perform respiratory exercises. Therefore, it will be compared to IMT on cardiac vagal modulation and pulse wave velocity on normotensive post menopause women.",[27,123,124],"Autonomic Imbalance","Vascular Stiffness","2024-06-20",{"date":127,"type":33},"2024-06-21",{"date":129,"type":33},"2023-09-01",{"date":131,"type":20},"2025-07-30",{"name":133,"class":40},"Instituto de Cardiologia do Rio Grande do Sul"]